POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 12/21/22

Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme Collaboration with OneThree Biotech identifies novel RSV treatments First time RSV drug candidates identified using AI Candidates with existing Pha...

Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg's Scientific Advisory Board to guide clinical development o...

POLB 001 LPS human challenge clinical trial successfully completed No serious adverse events reported Results of full data analysis expected in Q2 2023 LONDON, UK / ACCESSWIRE / December 12, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a leading infe...

Influenza Artificial Intelligence model build completed CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023 LONDON, UK / ACCESSWIRE / November 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a clinical stage infec...

LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and ...

Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund LONDON, UK / ACCESSWIRE / November 15, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ...

First time AI has been used to identify disease targets in RSV LONDON, UK / ACCESSWIRE / November 8, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, annou...

LONDON, UK / ACCESSWIRE / October 6, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been notified that Chief Executive Officer, Jeremy Skillington, has purch...

Continued expansion of IP portfolio enhancing protection of Poolbeg's growing pipeline LONDON, UK / ACCESSWIRE / October 4, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital lig...

Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change LONDON, UK / ACCESSWIRE / September 21, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company wit...